Regeneron Historical Income Statement
REGN Stock | USD 973.80 5.80 0.60% |
Historical analysis of Regeneron Pharmaceuticals income statement accounts such as Other Operating Expenses of 8.4 B, Operating Income of 4.2 B, EBIT of 4.2 B or Ebitda of 4.2 B can show how well Regeneron Pharmaceuticals performed in making a profits. Evaluating Regeneron Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Regeneron Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Regeneron Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regeneron Pharmaceuticals is a good buy for the upcoming year.
Regeneron |
About Regeneron Income Statement Analysis
Regeneron Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Regeneron Pharmaceuticals shareholders. The income statement also shows Regeneron investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Regeneron Pharmaceuticals Income Statement Chart
Regeneron Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Regeneron's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Regeneron Pharmaceuticals revenue and expense. Regeneron Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Regeneron Pharmaceuticals' EBIT is very stable compared to the past year. As of the 13th of May 2024, EBITDA is likely to grow to about 4.2 B, while Income Tax Expense is likely to drop about 169.5 M. Add Fundamental
Total Revenue
Total revenue comprises all receipts Regeneron Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Regeneron Pharmaceuticals. It is also known as Regeneron Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Regeneron Pharmaceuticals income statement and represents the costs associated with goods and services Regeneron Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Regeneron Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' EBIT is very stable compared to the past year. As of the 13th of May 2024, EBITDA is likely to grow to about 4.2 B, while Income Tax Expense is likely to drop about 169.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 4.7B | 5.6B | 7.1B | 7.4B | Cost Of Revenue | 2.4B | 1.6B | 883.7M | 927.9M |
Regeneron Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Regeneron Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Regeneron Pharmaceuticals income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 210.3M | 290.7M | 436.3M | 434.4M | 421M | 442.1M | |
Interest Expense | 30.2M | 56.9M | 57.3M | 59.4M | 73M | 76.7M | |
Total Revenue | 7.9B | 8.5B | 16.1B | 12.2B | 13.1B | 13.8B | |
Gross Profit | 7.1B | 7.4B | 13.6B | 10.6B | 12.2B | 12.8B | |
Other Operating Expenses | 5.7B | 4.9B | 7.1B | 7.2B | 8.0B | 8.4B | |
Operating Income | 2.2B | 3.6B | 8.9B | 4.7B | 4.0B | 4.2B | |
Ebit | 2.2B | 3.6B | 8.9B | 4.7B | 4.0B | 4.2B | |
Ebitda | 2.4B | 3.9B | 9.4B | 5.2B | 4.0B | 4.2B | |
Cost Of Revenue | 782.2M | 1.1B | 2.4B | 1.6B | 883.7M | 927.9M | |
Total Operating Expenses | 4.9B | 3.8B | 4.7B | 5.6B | 7.1B | 7.4B | |
Net Income | 2.1B | 3.5B | 8.1B | 4.3B | 4.0B | 4.2B | |
Income Before Tax | 2.4B | 3.8B | 9.3B | 4.9B | 4.2B | 4.4B | |
Total Other Income Expense Net | 219.3M | 233.8M | 379M | 119.9M | 152.2M | 159.8M | |
Income Tax Expense | 313.3M | 297.2M | 1.3B | 520.4M | 245.7M | 169.5M | |
Research Development | 3.0B | 2.7B | 2.9B | 3.6B | 4.4B | 4.7B | |
Selling General Administrative | 1.8B | 1.3B | 1.8B | 2.1B | 2.6B | 2.7B | |
Net Income Applicable To Common Shares | 2.1B | 3.5B | 8.1B | 4.3B | 5.0B | 5.2B | |
Net Income From Continuing Ops | 2.1B | 3.5B | 8.1B | 4.3B | 4.0B | 2.2B | |
Non Operating Income Net Other | 249.5M | 290.7M | 436.3M | 179.3M | 206.2M | 216.5M | |
Tax Provision | 313.3M | 297.2M | 1.3B | 520.4M | 385.3M | 584.1M | |
Interest Income | 13.7M | 88.1M | 45.8M | 160.1M | 417.7M | 438.6M | |
Net Interest Income | (30.2M) | (56.9M) | (57.3M) | 100.7M | 345.6M | 362.9M | |
Reconciled Depreciation | 210.3M | 235.9M | 286.2M | 341.4M | 408.1M | 279.0M |
Currently Active Assets on Macroaxis
XERS | Xeris Pharmaceuticals | |
IGM | iShares Expanded Tech | |
QCOM | Qualcomm Incorporated | |
QTEC | First Trust NASDAQ 100 Technology | |
BA | The Boeing |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share 33.89 | Revenue Per Share 122.574 | Quarterly Revenue Growth (0.01) | Return On Assets 0.0774 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.